Acer Therapeutics Inc. (ACER)
Company Info
Highlights
$16.15M
-$1.93
$0.90 - $0.90
$1.50
2.61%
2.87
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
ACER
N/A
N/A
N/A
N/A
N/A
N/A
N/A
^GSPC (Benchmark)
0.52%
6.32%
-1.44%
12.25%
12.45%
14.20%
10.84%
Monthly Returns
The table below presents the monthly returns of ACER, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| 2023 | -7.57% | -12.50% | -62.64% | 15.70% | 1.41% | 3.75% | -5.78% | 47.13% | -36.33% | 3.09% | 7.12% | 0.00% | -64.14% |
| 2022 | -11.18% | 22.47% | 16.94% | -28.97% | 16.02% | -47.28% | 10.74% | -3.25% | 2.96% | -8.63% | 0.00% | 97.64% | 10.09% |
| 2021 | 39.31% | -13.70% | -1.27% | -6.11% | 0.34% | -2.39% | -10.49% | 2.73% | -2.66% | -8.20% | -10.64% | 8.57% | -12.98% |
| 2020 | -5.24% | -13.68% | -39.33% | 20.60% | 27.92% | 11.73% | 8.75% | -28.95% | 8.68% | -15.28% | 10.25% | -2.60% | -34.66% |
| 2019 | 21.72% | -3.23% | 2.53% | -19.47% | -8.58% | -78.20% | -23.33% | -9.70% | 18.15% | -1.88% | 11.18% | 15.23% | -80.07% |
| 2018 | 42.17% | -9.14% | 7.71% | 6.38% | -12.20% | 20.00% | -16.67% | 78.22% | -3.87% | -26.78% | 1.46% | -12.18% | 45.27% |
| 2017 | 88.21% | -7.55% | -3.62% | -16.74% | 39.62% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ACER is 58, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Acer Therapeutics Inc. (ACER) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Acer Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Acer Therapeutics Inc. was 98.28%, occurring on Aug 25, 2023. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.28% | Aug 23, 2018 | 1260 | Aug 25, 2023 | — | — | — |
| -38.97% | Oct 17, 2017 | 42 | Dec 14, 2017 | 18 | Jan 11, 2018 | 60 |
| -26.92% | Jul 10, 2018 | 16 | Jul 31, 2018 | 5 | Aug 7, 2018 | 21 |
| -20.19% | Oct 2, 2017 | 2 | Oct 3, 2017 | 7 | Oct 12, 2017 | 9 |
| -14.12% | Feb 1, 2018 | 11 | Feb 15, 2018 | 20 | Mar 16, 2018 | 31 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Acer Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Acer Therapeutics Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -400.0%.
Valuation
The Valuation section provides an overview of how Acer Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ACER relative to other companies in the Biotechnology industry. Currently, ACER has a P/S ratio of 174.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ACER in comparison with other companies in the Biotechnology industry. Currently, ACER has a P/B value of 17.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |